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in Patients with Multiple Myeloma Undergoing Upfront
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Jin Seok Kim,1 Kihyun Kim,2 June-Won Cheong,1 Yoo Hong Min,1 Cheolwon Suh,3*
Hawk Kim,4 Deog Yeon Jo,5 Hun Mo Ryoo,6 Sung Soo Yoon,7 Jae Hoon Lee8* and the Korean
Multiple Myeloma Working PartyUpfront high-dose myeloablative chemotherapy followed by a single autologous stem cell transplantation
(ASCT) is the standard therapy for patients under the age of 65 years with newly diagnosed multiple myeloma
(MM). Because disease status after induction chemotherapy is variable, we evaluated the prognostic effect of
disease status before ASCT, especially in patients who were initially chemosensitive. We retrospectively ana-
lyzed the initially chemosensitive MM patients ($ partial remission [PR]) enrolled in the Korean Multiple Mye-
loma Working Party Web-based registration system (www.myeloma.or.kr). Between November 1996 and
January 2007, 197 MM patients (median age 53 years) were treated with induction chemotherapy followed
by a single ASCT. All patients received peripheral blood stem cell (PBSC) support after conditioning with mel-
phalan (Mel) alone. We considered those patients with no detectable M-protein regardless of the result of im-
munofixation to be in complete remission (CR) in this study. The median follow-up times were 29.2 months
(range, 5.4 to 103.8 months) from the day of diagnosis and 22.4 months (range, 0.4 to 96.0 months) from the
day of ASCT. Before ASCT, 63 patients (32%) were in CR and 134 (68%) were in partial remission (PR). The
patients in CR had significantly longer overall survival (OS) from the day of ASCT compared with those in PR
(P5 .0015). Among the patients who received induction chemotherapy with vincristine, adriamycin, and dexa-
methasone (n5 162), the same difference inOSwas seen between those inCR and those in PR beforeASCT (P
5 .0016). CR afterASCTalso predicted longerOS (P5.0135); however, patientswith continuedCRafterASCT
had significantly higherOS after ASCT comparedwith patient with induced CR after ASCTwho were in PR be-
fore ASCT (P5.0178). Multivariate analysis indicated that remission status pre-ASCT (CR vs PR) is a significant
prognostic factor for predicting OS after ASCT (P5.012, Cox proportional hazard analysis; odds ratio5 2.83;
95% confidence interval5 1.25 to 6.37).We conclude that patients with MMwho are in CR before ASCT have
a betterOS than those in PR before ASCT. ContinuedCR after ASCTmay be an important prognostic factor as
well. Our findings suggest that the development of more effective induction regimens, including novel antimye-
loma agents to improve initial response, should be pursued to enhance clinical benefits post-ASCT.
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464 Biol Blood Marrow Transplant 15:463-470, 2009J. S. Kim et al.INTRODUCTION in the primary refractory group achieved CR afterThe treatment of multiple myeloma (MM) has
improved strikingly over the last several decades
[1,2]. Although not curative, autologous stem cell
transplantation (ASCT) improves the likelihood of
a complete response (CR), prolongs progression-free
survival (PFS) and overall survival (OS), and represents
a major advance in MM therapy. Tandem ASCT in pa-
tients with newly diagnosed MM has shown a signifi-
cant survival benefit in several clinical trials. But only
those patients who fail to achieve very good partial re-
mission (PR) after the first ASCT should be offered
a tandem second ASCT, because a clear OS benefit
of tandem ASCT has not been demonstrated in any
randomized study other than the Itergroupe Franco-
phone du Myelome (IFM) 94 trial [1-5]. Patients at
high biological risk had particularly poor outcomes
even after tandem ASCT, indicating that tandem
ASCT may have only minimal additional benefit
even in high-risk MM patients [5,6]. Many centers
have adopted upfront high-dose myeloablative chemo-
therapy followed by a single ASCT as standard initial
treatment for patients under the age of 65 years with
newly diagnosed MM.
Among the many independent prognostic factors
for predicting survival of MM in the high-dose
ASCT era, cytogenetic abnormalities [eg, deletion of
chromosome 13, 11q, 17p abnormalities, hypodip-
loidy, t(4;14), t(14:16)] and the International Staging
System (ISS) are the most important [5-8]. ISS score,
determined from the start of the initial induction ther-
apy [8] and just before ASCT, has been found to be
correlated with OS after ASCT [9]. Although the
prognostic importance of the ISS is clear, practical
application of this system has been hampered by lack
of consideration of the biological risk factors (cytoge-
netic abnormalities) associated with MM. Evaluation
of cytogenetic abnormalities in newly diagnosed MM
patients also has some limitations related to lack of
standardization, high cost, and restricted availability.
Consequently, there is a need for simple clinical prog-
nostic markers that correlate with the biological risk of
MM.
CR is a main goal of ASCT, and many clinical trials
have attempted to achieve CR before ASCT through
more aggressive induction therapies, including novel
antimyeloma agents such as thalidomide, lenalido-
mide, and bortezomib. But, until recently, whether
CR before ASCT or after ASCT translates to better
survival has remained unclear [7,10,11]. Several studies
have shown that patients with primary refractory MM
can benefit from ASCT to the same extent as those
with responsive disease. This is because outcome
depends on the final response after transplantation
and is independent of the response to induction che-
motherapy. At the Mayo Clinic, 20% of the patientsASCT, compared with 35% of the patients in the che-
mosensitive group; the 2 groups had similar PFS [10].
This indicates that lack of response to initial induction
does not preclude a good response to ASCT. But,
according to the results of Total Therapy II from
Arkansas, MM patients with immunofixation-negative
CR at the time of first ASCT had a survival benefit
compared with those with only PR at the time of first
ASCT [11].
Is CR before ASCT a good surrogate for survival?
It should be noted that not all studies have shown an
absolute benefit from achieving CR before ASCT;
however, previous studies have evaluated the role of
response status before ASCT in both chemosensitive
and chemoresistant MM patients. In most cases, the
effect of ASCT is maximized in patients with chemo-
sensitive disease. Therefore, in this study, we evalu-
ated the prognostic effect of disease status before
ASCT only in those MM patients who were initially
chemosensitive. Specifically, we evaluated the prog-
nostic influence of pretransplantation characteristics
and pretransplantation disease status on disease sur-
vival in the initial induction chemosensitive MM pa-
tients ($ PR) who received an upfront single ASCT
and were enrolled in the Korean Multiple Myeloma
Working Party (KMMWP) Web-based registration
system.METHODS
Data Collection
We retrospectively analyzed MM patients who
were initially chemosensitive ($PR) and were enrolled
in the KMMWP Web-based registration system
(www.myeloma.or.kr). Between November 1996 and
January 2007, 197 patients with MM (median age 53
years; range, 20 to 69 years) were treated with induc-
tion chemotherapy followed by single ASCT at 8 insti-
tutions in Korea. All patients received peripheral blood
stem cell (PBSC) support after conditioning with mel-
phalan (Mel) alone. We evaluated the staging scores at
the time of diagnosis according to the Durie-Salmon
(DS) staging system and the ISS, which comprises
serum beta2-microblobulin (beta2M) and albumin
[12].
Patients
Patients were grouped into 2 categories: (1) those
demonstrating CR before ASCT (defined as an
achievement of no detectable M-protein) and (2) those
who were in PR before ASCT (defined as $ 50%
reduction in M-protein level). Most of the patients
(162; 82%) initially received infusional chemotherapy
with vincristine, doxorubicin, and dexamethasone
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(15%) received induction therapy including novel anti-
myeloma agents such as thalidomide or bortezomib. In
most of the patients (166; 84%), PBSCs were collected
after administration of high-dose cyclophosphamide
(Cy). PBSCs were mobilized with hematopoietic
growth factors, such as granulocyte-colony stimulat-
ing factor (G-CSF). In 6 patients, PBSCs were col-
lected using only G-CSF. All patients underwent
conditioning with Mel alone; a typical dose was 200
mg/m2. Twelve patients (6%) received Mel at a re-
duced dose of 100 to 140 mg/m2 because of advanced
age, renal insufficiency, or poor performance status.
All patients underwent a single ASCT with PBSC sup-
port (median CD341 stem cell dose, 8.42 106/kg) af-
ter conditioning with Mel alone. After disease
progression, salvage therapy was provided at the dis-
cretion of the attending physician.
Definitions of Response and Survival
Response was assessed using immunofixation-
based European Group for Blood and Marrow Trans-
plantation/International Bone Marrow Transplant
Registry (EBMT/IBMTR) criteria for patients treated
after 1998 [13] and older criteria (ie, electrophoretic
criteria for defining CR) for those treated before
1998. In this study, CR includes both CR by immuno-
fixation negativity and immunofixation-positive elec-
trophoretic CR (so-called ‘‘near CR’’). Because bone
marrow biopsy was not routinely performed to docu-
ment CR, bone marrow plasma cells were not included
in the definition of CR. PR required at least a 50%
decrease in the serum M-protein value or, in patients
without a serum M-protein measurement, a 90%
decrease in urine M-protein excretion.
In complete responders, any detectable M-protein
by immunofixation or routine electrophoresis and/
or the appearance of new bone lytic lesions also
constituted disease progression. Disease progression
required a . 25% increase in M-protein from nadir
levels (in the case of responders) or baseline levels (in
the case of nonresponders) and/or the appearance of
new bone lytic lesions. OS was measured from the
date of transplantation to the date of death or last
follow-up. Patients alive at last follow-up were cen-
sored from analysis of OS. Any death was defined as
an event regardless of cause. PFS was defined as the
time from transplantation to disease progression or
death. If a patient did not progress, then the endpoint
for PFS was the date of last follow-up, and the patient
was censored.
Statistical Analysis
The c2 test was used to compare nonnumerical
variables among the groups. In addition, PFS and OS
from the time of transplantation was evaluated usingKaplan-Meier analyses and Cox proportional hazards
models. Differences in these timed endpoints between
the aforementioned factors, as well between patients in
groups, were tested for statistical significance using the
2-tailed log-rank test. Any factors that had a P value\
.05 in the univariate analyses were carried forward for
exploration in the multivariate model. P values\ .05
were considered statistically significant. All calcula-
tions were performed using SPSS version 12.0 (SPSS
Inc, Chicago, IL).RESULTS
Patient Characteristics
A total of 197 patients (104 males [53%]; median
age, 53 years [range, 20 to 69 years]) with MM who
were initially chemosensitive ($ PR) and who under-
went an upfront single ASCT were enrolled in this
study. The median follow-up times were 29.2 months
(range, 5.4 to 103.8 months) from the day of diagnosis
and 22.4 months (range, 0.4 to 96.0 months) from the
day of ASCT. Before ASCT, 63 patients (32%)
achieved CR and 134 (68%) achieved PR. The baseline
characteristics of the patients at diagnosis are detailed
in Table 1; except for sex, these did not differ signifi-
cantly between the 2 patient groups. A significant
number of female MM patients were in CR before
ASCT (P 5 .014). In all, 14 patients (7%) were DS
stage II and 171 (88%) were DS stage III. The distri-
bution was similar between the 2 groups. The lower
ISS stages (I and II) did not correlate with CR before
ASCT (Table 1).
A total of 162 patients (82%) initially received VAD
infusions as induction chemotherapy. There was no
difference in the number of cycles of VAD induction
chemotherapy between the 2 groups (median, 3 cycles).
Twenty-nine patients (15%) received induction
therapy including a novel antimyeloma agent, such as
thalidomide or bortezomib (Table 2). The proportion
of patients receiving a novel antimyeloma agent as in-
duction chemotherapy was higher in the CR group
than in the PR group (25% vs 10%; P5 .005). The me-
dian time to transplantation from the diagnosis of MM
was 5.53 months in the entire cohort and was similar for
the 2 groups (P 5 .65; 5.6 months for CR vs 5.47
months for PR). A total of 181 patients (92%) under-
went ASCT within 12 months of the diagnosis of
MM. The PBSC harvesting regimen, the conditioning
regimen for ASCT, and the infused CD341 stem cell
dose did not differ significantly between the 2 groups
(Table 2). The overall treatment-related mortality
(TRM) was 1.5% (3 of 197 patients).Treatment Response
Sixty-five patients achieved CR after induction
chemotherapy. Among these, 57 patients maintained
Table 1. Baseline Characteristics of the Patients with MM
Characteristics Total Patients in CR before ASCT Patients in PR before ASCT P
Number 197 63 134
Age, years, median (range) 53 (20 to 69) 53 (37 to 69) 53 (20 to 68) NS
Age > 60 years 46 11 (18%) 35 (26%) NS
M:F 104:93 25:38 79:55 .014
Type
IgG 87 25 (40%) 62 (46%) NS
IgA 46 18 (29%) 28 (21%)
IgD 13 3 (5%) 10 (8%)
Light chain 44 14 (22%) 30 (22%)
Nonsecretory 7 3 (5%) 4 (3%)
DS
IA/IB 9/1 3/0 6/1 NS
IIA/IIB 12/2 5/1 7/1
IIIA/IIIB 124/47 38/16 86/31
ISS
I/II 39/78 16 (28%)/20 (35%) 23 (19%)/58 (47%) NS
III 65 22 (38%) 43 (35%)
MM indicates multiple myeloma; M, male; F, female; CR, complete response; ASCT, autologous stem cell transplantation; DS, Durie-Salmon; ISS, Inter-
national Staging System; NS, not significant.
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failed to maintain CR at the time of ASCT. Five addi-
tional patients who were not in CR after induction
chemotherapy achieved CR before ASCT (Table 2).
Of the 63 patients who were in CR before ASCT, 61
(97%) remained in CR after ASCT, whereas 86Table 2. Treatment and Response According to the Pre-ASCT Res
Total Patients in CR befo
Induction chemotherapy
VAD (median 3 cycles) 162 45 (
1 to 3 cycles 108 3
$ 4 cycles 53 1
Novel agents 29 16 (
VAD-Thalidomide 10
VAD + Velcade including regimen 14
Thalidomide-dexa 5
Others 6
Response after induction chemotherapy
CR 65 57 (
PR 117 4 (
SD/PD 10/1 1 (2
PBSC harvesting regimen
High-dose cyclophosphamide 166 49 (
G-CSF only 6
Others 25 1
Response before ASCT
CR/PR 63/134 63
Continued CR/induced CR 57/5 57 (92%
Continued PR/induced PR 113/10
Conditioning regimen
Melphalan, 200 mg/m2 185 59 (
Melphalan, reduced dose 12 4 (
CD34+ cell dose, median 8.42  106/kg 7.97 
< 2  106/kg 2 1 (
2 to 5  106/kg 25 6 (1
5 to 10  106/kg 69 25 (
$ 10  106/kg 53 15 (
Response after ASCT
CR 147 61 (
PR 41 2 (
SD/PD 2/2 0
SD indicates stable disease; PD, progressive disease; CR, complete response; PR
disease; PD, progressive disease; PBSC, peripheral blood stem cell; VAD, vin
stimulating factor; NS, not significant.patients (64%) who were in PR before ASCT achieved
CR after ASCT (Table 2).
Survival
The median OS from the day of ASCT was 22.4
months (range, 0.4 to 96.0 months), and median PFSponse
re ASCT (n 5 63) Patients in PR before ASCT (n 5 134) P
.005
74%) 117 (90%)
3 75
2 41
25%) 13 (10%)
6 4
7 7
3 2
2 4
< .001
92%) 8 (6%)
7%) 113 (86%)
%)/0 9 (7%)/1(1%)
NS
78%) 117 (88%)
2 4
2 13
< .001
/0 0/134
)/5 (8%)
113 (86%)/10(8%)
NS
94%) 126 (94%)
6%) 8 (6%)
106/kg 8.83  106/kg NS
2%) 1 (1%)
3%) 19 (19%)
53%) 44 (43%)
32%) 38 (37%)
< .001
97%) 86 (64%)
3%) 39 (29%)
/0 2 (2%)/2 (2%)
, partial remission; ASCT, autologous stem cell transplantation; SD, stable
cristine, doxorubicin, and dexamethasone; G-CSF, granulocyte-colony
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78.2 months). The prognostic factors found to be sig-
nificant for posttransplantation OS in univariate analy-
ses are listed in Table 3. There were no significant
differences in OS or PFS according to immunoglobulin
subtype (ie, IgG, IgA, IgD, kappa light chain, lambda
light chain, and nonsecretory type). The initial DS
stage did not correlate with OS from the day of
ASCT (P5 .433), but initial low ISS stage (I or II) cor-
related with increased OS (P5 .029). In addition, PFS
after ASCT was not predicted by the initial DS stage
(P 5 .613), but was well predicted by the ISS (P 5
.04) (Table 3). Most of the patients (181 of 197; 92%)
underwent ASCT within 12 months of the diagnosis
of MM, and early ASCT was not a significant prognos-
tic factor for OS or PFS in this study.
OS was more significantly correlated with CR
before ASCT compared with PR before ASCT
(P5 .0015) (Figure 1A). According to remission status
before ASCT in the patients who received VAD induc-
tion chemotherapy (n5 162), OS also was significantly
correlated with CR before ASCT (P 5 .0016)
(Figure 1B). Achievement of CR after ASCT predicted
improved OS (P 5 .0135) (Figure 1C), but MM
patients with continued CR after ASCT had signifi-
cantly higher OS after ASCT compared with those
with induced CR after ASCT who had achieved PR
before ASCT (P 5 .0178) (Figure 1D). Similar results
also were obtained in the 162 MM patients who
received VAD induction chemotherapy (P 5 .0034,
CR after ASCT vs PR after ASCT; P5 .0296, contin-
ued CR after ASCT vs induced CR after ASCT).
Except for initial ISS, no other prognostic factors
for PFS were identified in this study. CR before
ASCT was not predictive of improved PFS compared
with PR status (Table 3).
Multivariate analysis indicated that disease status
before ASCT (CR vs PR) was a significant prognostic
factor for OS after ASCT (P5 .012, Cox proportionalTable 3. Prognostic Factors for OS and PFS after ASCT
Prognostic Factor OS PFS
Sex (male vs female) 0.913 0.178
Age at diagnosis (> 60 years vs # 60 years) 0.905 0.697
DS stage at diagnosis 0.433 0.613
ISS stage at diagnosis (I-II vs III) 0.029 0.040
Immunoglobulin type 0.093 0.058
Induction chemotherapy (VAD vs novel agents) 0.526 0.749
Status after induction chemotherapy 0.145 0.551
Time to transplantation from the diagnosis of
MM(< 12 months vs $ 12 months)
0.827 0.334
CD34+ stem cell dose 0.361 0.915
Status before ASCT (CR vs PR) 0.0015 0.995
Status after ASCT (CR vs PR) 0.0135 0.156
OS indicates overall survival; ASCT, autologous stem cell transplanta-
tion; DS, Durie-Salmon; ISS, international Staging System; VAD, vincris-
tine, doxorubicin, and dexamethasone; MM, multiple myeloma; CR,
complete response; PR, partial remission.hazard analysis; odds ratio 5 2.83; 95% confidence
interval 5 1.25 to 6.37).DISCUSSION
Because ASCT is usually performed as a consolida-
tion therapy in several hematologic malignancies,
theoretically the effect of ASCT is much greater in
patients who are sensitive to initial induction chemo-
therapy than in chemoresistant patients. Although sev-
eral studies have found that MM patients who were
poorly responsive to initial induction therapy
benefited from ASCT to the same extent as those
with responsive disease [7,10], the use of ASCT in
patients who are initially chemosensitive to prolong
the duration of disease control is logical, because
ASCT has no graft-versus-myeloma effect, unlike allo-
geneic transplantation. Patients achieving CR or at
least very good PR (VGPR) had longer OS compared
with patients who had only PR. This finding was con-
firmed in several previous trials [4]. Therefore, we
evaluated the effect of depth of initial response before
ASCT on the final survival outcome only in chemosen-
sitive ($ PR) MM patients. We also selected MM
patients who underwent a single ASCT with Mel alone
as the conditioning regimen. Thus, the MM patients
who were selected in this retrospective study should
be suitable for evaluating the prognostic role of re-
sponse status before ASCT.
We found no significant differences in OS or
PFS according to the time to ASCT from the di-
agnosis of MM; however, we cannot evaluate the
role of the time to ASCT from the diagnosis of
MM on OS, because fewer patients underwent
ASCT after 12 months (only 8%). Although initial
low ISS stage (I or II) predicted increased OS after
ASCT, achievement of CR before ASCT was the
sole prognostic factor for predicting improved
OS according to our multivariate analysis. Most
of the patients (162; 82%) initially received VAD
infusion as induction chemotherapy, and our find-
ings also confirm the role of CR before ASCT in
MM patients who received VAD induction chemo-
therapy. Achievement of CR after ASCT also was
important; however, achievement of CR by the
time of ASCT was more important, because pa-
tients who achieved CR after ASCT (induced CR
patients) had reduced survival compared with those
who maintained their CR response after ASCT
(continued CR patients) (Figure 1D). MM patients
with high biological risks have poor outcome, and
these biological risk factors are important prognos-
tic factors for predicting OS [1,5,14]; however, the
negative effect of these cytogenetic abnormalities
on OS is not overcome by ASCT [5]. Thus, the
achievement of CR before ASCT is more
Figure 1. OS curves of 197 MM patients after ASCT (Kaplan-Meier curves). (A) OS after ASCTaccording to the response status before ASCT. (B) OS
according to the response status before ASCT in the MM patients who received VAD induction chemotherapy (n 5 162). (C) OS according to the
response status after ASCT. (D) OS according to the continuity of CR after ASCT in the MM patients who achieved CR after ASCT (n 5 147).
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ASCT, especially in MM patients with cytogenetic
abnormalities. Importantly, \ 5% of the MM pa-
tients who received VAD induction chemotherapy
achieved CR before ASCT [1]. Furthermore, there
have been numerous clinical demonstrations of in-
creased CR rate and the ability to overcome bio-
logical risks (eg, cytogenetic abnormalities) in
patients who received novel agents as induction
therapy [5,14-17]. Therefore, novel agents should
be incorporated into the induction regimen for
newly diagnosed younger MM patients. Among
these agents, thalidomide-dexamethasone induction
therapy demonstrated a modest benefit compared
with VAD or high-dose dexamethasone, with sim-ilar rates of CR before ASCT and OS after ASCT
[18,19]; however, lenalidomide- and bortezomib-
based regimens demonstrated very high CR rates
before ASCT [20-23]. These high CR rates are
comparable with those achieved with single
ASCT and could be converted to even higher
CR rates after ASCT. Therefore, lenalidomide-
or bortezomib-based regimens may be a new stan-
dard of care for pre-ASCT therapy. In our study,
the use of novel antimyeloma agents as induction
chemotherapy was more common in patients in
CR before ASCT than in patients in PR before
ASCT (25% vs 10%; P 5 .005), but we found
no difference in OS between patients who received
VAD as induction chemotherapy and those who
Biol Blood Marrow Transplant 15:463-470, 2009 469CR before ASCTas a Prognostic Marker in MMreceived novel agents. We cannot evaluate the role
of novel agents on OS in this study, because the
patients who received novel agents were fewer in
number and follow-up was of relatively short dura-
tion. We also were not able to evaluate the role of
consolidation treatment with novel agents in MM
patients in PR before ASCT.
Currently, the ISS is the most important validated
independent prognostic model for determining sur-
vival in MM; however, its practical application has
been limited by the absence of other biological risk
factors, including cytogenetic abnormalities, as well
as newer tools, such as gene expression profiling.
Consequently, evaluation of biological risk factors
in patients with newly diagnosed MM is important
for predicting OS [5,14]. But many questions remain
regarding the proper and appropriate tests for these
biological markers in patients with newly diagnosed
MM, given the associated high costs and need for
highly trained personnel. Thus, we did not use cyto-
genetic analysis results in this study. Nonetheless,
based on our findings, it is likely that clinical response
before ASCT reflects these biological risks. MM pa-
tients in PR before ASCT likely have greater biolog-
ical risks compared with those patients in CR before
ASCT and thus cannot maintain their survival even
after ASCT.
Examination of early OS after ASCT (median
follow-up period, approximately 2 years) appears to fa-
vor those patients who were in CR before ASCT, but
the interpretation of these findings is limited by
a lack of clinical data on consolidation treatment after
ASCT, maintenance treatment after ASCT, and sal-
vage treatment. However, we did evaluate a relatively
large number of MM patients who were enrolled
from several institutions and also carefully selected rel-
atively homogenous patients according to initial anti-
myeloma treatment, including ASCT regimen, so we
could use the response status before ASCT to predict
early OS after ASCT.
We conclude that chemosensitive MM patients
who underwent an upfront single ASCT and were in
CR before ASCT had better OS than those patients
who were in PR before ASCT. Continued CR after
ASCT may be an important prognostic factor. Thus,
the adoption of more effective induction regimens,
including novel antimyeloma agents that might over-
come some biological risk, to improve initial response
should be pursued to enhance clinical benefits after
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